Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gynecologic 1

Conditions

Neoplasms 2Neoplasm Metastasis 2Hemangiosarcoma 2Gastrointestinal Neoplasms 2Colorectal Neoplasms 2Carcinoma, Renal Cell 2Breast Neoplasms 2Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Sarcoma, Endometrial Stromal 1Sarcoma 1Rectal Neoplasms 1Prostatic Neoplasms 1Pathologic Complete Response 1Ovarian Neoplasms 1Oligodendroglioma 1Gliosarcoma 1Glioblastoma 1Fallopian Tube Neoplasms 1Colonic Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma 1Brain Neoplasms 1Advanced Hepatocellular Carcinoma 1

Interventions

trebananib 1selurampanel 1saracatinib 1perifosine 1elacestrant 1Trabectedin 1Thalidomide 1Temozolomide 1Sunitinib 1RAD1901 1Postmortem Imaging 1Paclitaxel 1Mass Spectrometry 1Magnetic Resonance Spectroscopy 1Injections 1Imatinib Mesylate 1Ifosfamide 1High-Energy Shock Waves 1Fulvestrant 1Doxorubicin 1Chromatography, High Pressure Liquid 1Biopsy 1BI 2536 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Sarcoma, Endometrial Stromal × trebananib × Clear all
NCT01210222 2018-02-23

Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer

GOG Foundation

Phase 2 Completed
35 enrolled 9 charts
GynecologicSarcoma

Sarcoma, Endometrial Stromal

Data powered by HemOnc (CC BY 4.0) Colophon âš¡